3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
7
Phase 3
4
Phase 2/3
1
Phase 1/2
1
Phase 1
1
Status
Completed
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Thoracic
1
CNS
1
Conditions
Carcinoma, Non-Small-Cell Lung
3
NSCLC
2
Brain Neoplasms
2
Respiratory Tract Diseases
1
Neoplasms
1
Lung Neoplasms
1
Colorectal Neoplasms
1
Interventions
Trimethoprim, Sulfamethoxazole Drug Combination
4
gamma-Globulins
3
Standard of Care
3
Oxaliplatin
3
Melatonin
3
Gemcitabine
3
Fluorouracil
3
Drug Therapy
3
Ciprofloxacin
3
Capecitabine
3
pertuzumab
2
entrectinib
2
cobimetinib
2
capmatinib
2
atezolizumab
2
alectinib
2
Water
2
Vemurafenib
2
Trastuzumab
2
Sirolimus
2
Saline Solution
2
Pemetrexed
2
Methylphenidate
2
Lidocaine
2
Leucovorin
2
Immunoglobulins, Intravenous
2
Docetaxel
2
Dexmedetomidine
2
Cisplatin
2
Carboplatin
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Phase 2/3
×
Neoplasms
×
Gefitinib
×
Clear all
NCT03653546
2025-09-10
BM
Alpha Biopharma (Jiangsu) Co., Ltd.
Phase 2/3
Completed
492 enrolled